Pro 2014-003 (Announcement of Jianfeng Group's Guarantee to Holding Subsidiary)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2014-003
Announcement of Zhejiang Jianfeng Group Co., Ltd.
Providing Guarantee to Holding Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Tips
● Names of Guarantees: Daye Jianfeng Cement Co., Ltd., Zhejiang Jianfeng Pharmaceutical Co., Ltd., Jinhua Pharmaceutical Co., Ltd., Zhejiang Jianfeng International Trading Co., Ltd., Yunnan Jianfeng Cement Co., Ltd.
● Proposed guarantee amount: set guarantee amount of 0.5 billion yuan.
● Is there any counter-guarantee for this guarantee: No
● Cumulative number of overdue external guarantees: No
Overview of 1. guarantees
On April 11, 2014, Zhejiang Jianfeng Group Co., Ltd. held the 14th meeting of the 8th Board of Directors. Nine directors should be present at the meeting. Independent director Deng Mingran entrusted independent director Liu Jiajian to attend the meeting due to a business trip, and the remaining eight directors attended the meeting in person; they complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the "Proposal on Providing Guarantees for Holding Subsidiaries" was reviewed and passed with 9 votes in favor, 0 votes against, and 0 abstentions. Basic information of
2. guarantor
, Zhejiang Jianfeng Pharmaceutical Co., Ltd., with a registered capital of 149.07 million yuan, of which: the company accounts for 99.16, and its registered address is in Jinhua Industrial Park, Zhejiang Province. Its main business is the manufacture, sale and export of eye drops, ear drops, large volume injection, small volume injection and bulk drugs (azithromycin sulfate, L-aspartate amlodipine, paroxidine hydrochloride), freeze-dried powder injection, powder injection (cephalosporins), tablet, hard capsule, granule, ointment, dropping pill, bulk drug , etc. .
2. daye peak cement co., ltd. has a registered capital of 0.25 billion yuan, of which the company accounts for 6% and the company's holding subsidiary Zhejiang peak cement co., ltd. (the company holds 95.25) accounts for 70%. registered address: daye city hubei province security town; main business: cement, cement clinker, cement mechanical and electrical equipment manufacturing and sales; building materials products such as sales.
. Yunnan Jianfeng Cement Co., Ltd. has a registered capital of 0.15 billion yuan, of which: the company accounts for 75%, the holding subsidiary Jianfeng Cement (the company holds 95.25) accounts for 25%, and its registered address is 43 kilometers from Silan Highway, Liushun Township, Simao District, Pu 'er City, Yunnan Province. Its main business is cement production; sales of cement and cement products, building materials, gravel, woven bags, cement grinding; cement export trade.
. Jinhua pharmaceutical co., ltd. has a registered capital of 22 million yuan, of which: Zhejiang Jianfeng pharmaceutical co., ltd., the controlling subsidiary of the company, accounts for 90% and the company accounts for 10%. its registered address is 1180 huancheng east road, Jinhua city. Main business: drug business. Prepackaged food, hazardous chemicals, medical devices, etc. The drug business license mainly includes: sales of Chinese patent medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. .
5, Zhejiang Jianfeng International Trade Co., Ltd., with a registered capital of 30 million yuan, of which: 93.33 of our company and 6.67 of Jianfeng Pharmaceutical Co., Ltd., registered address: 88 changchun West Road, Jindong Economic Development Zone, Zhejiang Province, mainly engaged in: licensed business items: freight transportation: general cargo transportation; Station yard: freight station (yard) operation (freight loading, storage and tally) (road transport operation license is valid until 2015 9 July 5 ). General business items: import and export of goods and technologies, sales of pharmaceutical intermediates, pharmaceutical equipment, daily chemicals, textiles, etc. that are permitted by national laws and regulations and do not require pre-approval; public bonded warehouse operation; business permitted by national laws and policies Consulting service activities (except futures, securities, and financial business consulting); carry out international transportation agency business for import and export goods.
Key audited 2013 financial data of the above subsidiaries (in: ten thousand yuan)
company name |
total assets |
asset-liability ratio% |
total operating income |
net profit attributable to owner of parent company |
Zhejiang Jianfeng Pharmaceutical Co., Ltd. |
83321.11 |
62.80 |
92418.02 |
3190.88 |
Daye Jianfeng Cement Co., Ltd. |
68282.37 |
33.71 |
62850.24 |
10531.00 |
Yunnan Jianfeng Cement Co., Ltd. |
55484.50 |
74.68 |
30852.77 |
1057.59 |
Jinhua Pharmaceutical Co., Ltd. |
32640.47 |
78.60 |
65684.78 | 290.07
|
The main contents of the guarantee provided by the 3.
1. Guarantee the loans of the holding subsidiary to financial institutions, set the following limits:
The guarantee within the above amount authorizes the chairman to execute it in batches.
above matters shall be submitted to the shareholders' meeting for deliberation.
4. the opinion of the board of directors
The above guaranteed companies are all controlling subsidiaries of the company. The company can effectively control the guarantee risks, and the board of directors agrees to the above guarantees. The three independent directors of the company issued an independent opinion that was expressly agreed.
5. Cumulative Number of External Guarantees and Number of Overdue Guarantees
As of the disclosure date of this announcement, the total amount of external guarantees approved by the company and its controlling subsidiaries is 650 million yuan, accounting for 37.42 of the total owner's equity attributable to the parent company in 2013 audited consolidated caliber. The total amount of guarantee approved by the company to the holding subsidiary is 400 million yuan, accounting for 23.03 of the total owner's equity attributable to the parent company in 2013.
As of the disclosure date of this announcement, the actual balance of external guarantees of the company and its controlling subsidiaries was 350 million yuan, accounting for 20.15 of the total owner's equity attributable to the parent company by the audited consolidated caliber in 2013; The actual balance of the company's guarantee to the holding subsidiary is 80 million yuan, accounting for 4.61 of the total owner's equity attributable to the parent company by the audited consolidated caliber in 2013.
As of the disclosure date of this announcement, the company has no overdue guarantee.
6. Reference Document Catalogue
1
, Resolution of the 14th Meeting of the 8th Board of Directors of the Company;2
, copy of the business license of the guarantor;hereby announces
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 15, 2014
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05